PURPOSE: To obtain the subject low-toxic new compd. useful as a therapeutic drug for cardiovascular diseases such as heart failure and hypertension.
CONSTITUTION: This invention provides a compd. expressed by formula I or its salts, and the compd. is, for example, 3β-(2-trimethylsilyl ammonium- ethoxy)-17β-(3-furyl)-5β-androstan-14β-ol-chloride. In formula I, double lines of dot lines and solid liens represent single bonds or double bonds; X is O or S; R is quaternary ammonium, 2-(2-imidazolynyl) or the like; R1 is H, hydroxy or the like; R2 is H or bonded with R1 to form oxirane ring; However, when X=S, the wavy line on 3-position forms b-steric configuration. The compd. is obtd. by condensation of a compd. expressed by formula II with a compd. expressed by R-Y (Y is an electron attractive group). The condensation reaction is preferably carried out in an inert aprotic solvent such as THF in the presence of a strong base such as hydrogenated sodium at 10 to 110°C.
| JP2004519506 | Esmolol prescription |
| WO/2008/100457 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS |
| JP2023550597 | Bicyclic pyridazinones as thyroid hormone receptor beta (TR-β) agonists |
RUIJI BERUNARUDEI
PATORITSUIA FUERAARI
MAURO GOBIINI
PIERO MEROONI
ROREDANA BUARENTEINO
